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Effect of Polymer Molecular Weight on the Bone
Biological Activity of Biodegradable Polymer/Calcium
Phosphate Cement Composites
Esther W.H. Bodde, M.D., Ph.D.,1 Wouter J.E.M. Habraken, Ph.D.,1 Antonios G. Mikos, Ph.D.,2
Paul H.M. Spauwen, M.D., Ph.D.,3 and John A. Jansen, D.D.S., Ph.D.1
Previous studies demonstrated that the addition of biodegradable polymer microparticles to calcium phosphate
(CaP) cement improves the cement’s degradative behavior without affecting its handling characteristics, especially
its injectability and moldability. We investigated the influence of molecular weight of polymeric microparticles
included in CaP cement on implant degradation and bone formation in critical-sized defects. Forty rats received
cranial defects filled with formulations of CaP cement and poly(DL-lactic-co-glycolic acid) (PLGA) microparticles.
Microparticles consisted of 100% high- (HMW) or low-molecular-weight (LMW) PLGA or mixtures of these (25%,
50%, or 75%). Implantation time was 12 weeks. Porosity measurements showed that the 100% HMW group was
significantly less porous than the other groups. Histology and histomorphometry revealed significantly greater
implant degradation in the 100% LMW group. Defect bridging was mainly seen in the 75% and 100% LMW groups,
with the highest amount of bone in the 100% LMW formulation. These results suggest that LMW PLGA micro-
particles are associated with better bone formation than HMW PLGA, which is most likely explained by the greater
degradation of LMW PLGA microparticles. In conclusion, CaP cement composites with high percentages of LMW
PLGA microparticles show good bone transductive behavior, with complete defect bridging. The 100% LMW
group turned out to be the best formulation.
Introduction
Calcium phosphate (CaP) cements can be good bonegraft substitutes to fill bone defects; obtain fracture
stability; or fixate prostheses in dental, orthopedic, or recon-
structive surgery applications because of their biocompati-
bility and capability for osteoconduction.1–4 Before setting,
the paste can be molded in the desired shape, or it can be
directly injected and harden in situ. A disadvantage of the
cement, however, is its poor biomechanical and biodegrada-
tion behavior.5–8
The degradation rate of cement can be improved by in-
creasing its porosity and thereby increasing the specific
surface area and the possibility for cells to enter the scaffold.9
There are several ways to create macropores in cement, but
the injectable and moldable properties are not always
maintained. A technique to create macropores without losing
the handling properties is the inclusion of biodegradable
polymeric microparticles.10–12 The microparticles will ini-
tially stabilize the cement but will also degrade over time,
leaving macropores behind. The use of poly(DL-lactic-
co-glycolic acid) (PLGA) as source for porogens is a favor-
able possibility, because these microparticles can be used as a
delivery vehicle for growth factors and to further enhance
the bone regenerative effect of the CaP cement.13,14 It must be
emphasized that the inclusion of PLGA microparticles is not
intended to increase the mechanical properties of the CaP
cement. This must be achieved by the degradation of the
PLGA micropartcles and the subsequent ingrowth of bone.
In a previous study, CaP cement with PLGA microparticle
composites were implanted subcutaneously and in non-
critical-sized (3.5 mm in diameter) cranial defects in rats. The
study showed that high-molecular-weight (HMW) PLGA
degraded in vivo and that the pores formed subsequently
allowed ingrowth of soft and hard tissue throughout the
specimens after 12 weeks of implantation.12 For the further
evaluation of the regeneration capacity of the composite,
the material was recently investigated in critical-sized (8 mm
in diameter) cranial defects in rats.15 In these implants, in-
growth of bone and soft tissue was seen only superficially
and not in the center, even after 12 weeks of implanta-
tion. Evidently, the degradation of the microparticles in the
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‘‘critical-sized implants’’ differed from that in the previous
‘‘non-critical-sized implants’’. Therefore, to optimize the
composite material, the degradation of the microparticles
should be increased.
One option to vary the degradation pattern of polymeric
microspheres is to change the molecular weight of PLGA
(e.g., low-molecular-weight (LMW) PLGA degrades faster
than high HMW PLGA.16 A mixture of LMW and HMW
PLGA might be the optimal combination for initial stabili-
zation and implant degradation over time, leading to greater
bone formation in critical-sized defects than with a com-
posite of CaP cement and solely HMW PLGA.
Based on the considerations mentioned above, the purpose
of the present study was to determine the influence of dif-
ferent molecular weights of PLGA microspheres on implant
degradation and bone ingrowth in CaP cement implants
placed in critical-sized bone defects in rats. We hypothesized
that a high percentage of LMW PLGA microparticles in the
CaP cement would result in an better osseotransductive




The CaP cement (Calcibon, Biomet Merck, Darmstadt,
Germany) consisted of 61% alpha-tricalcium phosphate, 26%
dicalcium phosphate dihydrate, 10% calcium carbonate, and
3% precipitated hydroxy apatite. The cement powder was
sterilized using gamma radiation with 25 kGy (Isotron B.V.,
Ede, The Netherlands). The cement liquid applied was a
filter-sterilized (0.2-mm filter) 1% aqueous solution of sodium
phosphate. Poly (DL-lactic-co-glycolic acid) (PLGA) (Pur-
asorb, Purac, Gorinchem, The Netherlands) with a lactic to
glycolic acid ratio of 50:50 and an average molecular weight
(Mw) of 54.21 1.34 kDa (HMW) and 4.55 0.03 kDa (LMW)
was used for the microparticle preparation. The number
average molecular weights and polydispersity index of the
polymers were 34.73 0.38 kDa and 1.56 0.03, respectively,
for HMW and 2.84 0.003 kDa and 1.60 0.01, respectively,
for LMW.
Preparation of PLGA microparticles
To prepare PLGA microparticles, a double-emulsion
solvent-extraction technique ([water in oil] in water) was
used.11,13,17–19 HMW PLGA microparticles were produced
by injecting 500mL of distilled water into a tube containing a
solution of 1.0 g of HMW PLGA in 4 mL of dichloromethane.
The mixture was emulsified for 60 s on a vortexer. Accord-
ingly, LMW PLGA microparticles were produced by adding
500 mL of distilled water to 1400 mg of LMW PLGA in 2 mL
of dichloromethane to obtain microparticles of similar sizes
as the HMW PLGA. Then 6 mL of 0.3% aqueous poly (vinyl
alcohol) (PVA, Acros Organics, Geel, Belgium) solution was
added and emulsified for another 60 s to produce the second
emulsion. This mixture was added to 394 mL of 0.3% PVA
solution and 400 mL of 2% isopropyl alcohol solution and
was stirred for 1 h. The evaporation of the solvent resulted in
precipitation of the dissolved polymer, and microparticles
were subsequently formed. The microparticles were allowed
to settle for 15 min, and the solution was decanted. Then the
microparticles were collected through centrifugation at
1500 rpm for 5 min, lyophilized to dryness, and stored under
argon at 208C until use. The size distribution of the PLGA
microparticles was determined using image analysis (Leica
Qwin, Leica Microsystems, Wetzlar, Germany). Scanning elec-
tron micrography (SEM) images of the microparticles were
made at the Microscopic Imaging Center of the Nijmegen Cen-
ter for Molecular Life Sciences (Nijmegen, The Netherlands).
Preparation of CaP cement implants
The PLGA microparticles were mixed with the CaP cement
powder in a proportion of 20 wt.%, because a previous study
indicated this as the best ratio.11 Different ratios of HMW to
LMW PLGA microparticles were used, corresponding to the
different groups: I. 100% HMW PLGA (100HMW); II. 25%=
75% LMW=HMW PLGA (25LMW); III. 50%=50% LMW=
HMW PLGA (50LMW); IV. 75%=25% LMW=HMW PLGA
(75LMW) and V. 100% LMW PLGA (100LMW). The cement
was created by adding 1 wt.% sodium phosphate to the
PLGA=CaP powder mixture using a 2-mL syringe (BD Plas-
tipak, Becton Dickinson S.A., Madrid, Spain) with a closed tip
and shaking these components for 15 s using a mixing appa-
ratus (Silamat, Vivadent, Schaan, Liechtenstein). The ratio
of liquid to powder ranged from 0.35 for the 100% HMW
to 0.5 for the 100% LMW groups. The cement was immedi-
ately injected into Teflon molds with a standardized shape
(7.8 mm 1.8 mm). After setting at room temperature over-
night, the implants were removed from the molds. SEM im-
ages ( Jeol JSM 633OF) were made of the composites at the
Department of Natural Sciences of the Radboud University
(Nijmegen, The Netherlands).
Porosity measurements
The macroporosity and total porosity were determined for
the different implant formulations. PLGA–CaP cement sam-
ples (n¼ 6) were placed in a furnace at 6508C for 2 h, to burn
out the polymer. Then, by weighing the implants, the total
porosity and macroporosity could be calculated using equa-








 100% Equation 2
Where
etot¼ total porosity (%)
emacro¼macroporosity (%)
mburnt¼ average mass sample (after burning out polymer)
(g)
mmicroporous¼ average mass microporous sample (g)
V¼volume sample (cm3)
rHAP¼density hydroxy apatite (g=cm3)
Surgical procedure
Forty healthy young-adult (*8 weeks old) male Wistar
rats weighing 265 10 g were included as experimental
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animals. National guidelines for the care and use of labora-
tory animals were observed. The Experimental Animal Com-
mittee of the Radboud University reviewed and approved
the research.
Anesthesia was induced and maintained using isoflurane
inhalation (Rhodia Organique Fine Limited, Avonmouth,
Bristol, England). To minimize postoperative discomfort,
0.02 mg=kg of buprenorphine (Temgesic, Reckitt Benckiser
Health Care Limited, Schering-Plough, United Kingdom)
was administered intraperitoneally before surgery and sub-
cutaneously for 2 days after surgery.
After anesthesia, each rat was immobilized on its abdo-
men, and the skull was shaved and disinfected with chlor-
hexidine. A longitudinal incision was made from the nasal
bone to the occipital protuberance. To minimize pain, Lido-
caine HCL 1% (B. Braun, Melsungen, Germany) was dripped
at the periosteum before incision and exposure of the parietal
bone. A full-thickness bone defect was created in the dorsal
part of the parietal cranium central to the sagittal suture with
a dental drill machine (Elcomed 100, W&H Dentalwerk
Salzburg, Austria) with a trephine burr (ACE Dental Implant
System, Brockton, MA) with an outside diameter of 8.0 mm.
An earlier study showed that this diameter is critically sized
after 12 weeks of implantation.15 The bone defect was drilled
under continuous saline cooling and with care for the un-
derlying dura mater and sagittal sinus. After removing the
bone segment, an implant was placed. Although CaP cement
can be injected in vivo, in the present study, we choose pre-
hardened implants because the cranial defect model did not
allow for injection because of the thin bone rim and fragile
underlying dura mater. The rats were randomly assigned to
one of the five groups (n¼ 8 for each implant and time pe-
riod). The periosteal tissue was closed using nonresorbable
Prolene 5-0 (Ethicon Inc, Somerville, NJ) suture material. The
skin was closed with resorbable Vicryl 4-0 sutures ( Johnson
& Johnson, St.Stevens-Woluwe, Belgium). Implantation time
was 12 weeks.
Four rats in each group received in vivo fluorochromes.
Tetracycline (yellow), calcein (green), and alizarin complex-
on (red) were administered subcutaneously (25 mg=kg), re-
spectively 1, 6, and 11 weeks after surgery.
The animals were housed individually in cages. Intake of
fluids and food was monitored in the first days postopera-
tively, and the animals were observed for signs of pain, in-
fection, and proper activity. At the end of the implantation
time, the rats were sacrificed using an overdose of carbon
dioxide.
Histology and histomorphometrical procedures
After sacrifice, implants with surrounding tissue were re-
trieved, fixed in phosphate-buffered formaldehyde solution
(pH 7.4) and dehydrated in increasing ethanol concentrations
(70–100%). The majority of the specimens (6=8) were embed-
ded in methylmethacrylate (non-decalcified). Multiple thin
sections (10 mm) were prepared perpendicularly at different
levels through the implants using a microtome with diamond
blade (Leica Microsystems SP 1600, Nussloch, Germany).
These slides were stained with methylene blue and basic
fuchsin. At least three sections of each implant were examined
with light microscopy (Leica Microsystems AG, Wetzlar,
Germany). In addition, the sections were quantitatively
scored using computer-based image analysis techniques
(Leica Qwin Pro-image analysis system). From digitalized
images (magnitude 1.6x), the amount of remained cement and
newly formed bone were determined within the region of
interest (a standardized area within the boundaries of the
implants). As a reference for the initial (t¼ 0) quantity of ce-
ment, nonimplanted samples (n¼ 6) were scored as well. The
amounts of cement and newly formed bone were expressed as
a percentage of the region of interest. All data as presented are
the average of the measurements of the three evaluated sec-
tions for each sample.
From the specimens of the rats that received fluoro-
chromes in vivo, two additional unstained sections were
prepared and analyzed using a reflectant fluorescence mi-
croscopy with an excitation filter of 470 to 490 nm (Leica
Microsystems AG).
Two of the eight specimens were fixed in 10% buffered
formalin (pH 7.4) for 2 days, decalcified in ethylenedini-
trilotetraacetic acid (EDTA, Merck KGaA, Darmstadt, Ger-
many) for 6 days, dehydrated through graded ethanols, and
embedded in paraffin. Using a microtome (Leica RM 2165,
Leica Microsytems, Nussloch, Germany), thin (6 mm) per-
pendicular sections were prepared and stained with hema-
toxylin and eosin. In addition, a Goldner’s Masson trichrome
stain was used to distinguish connective tissue and the
mineralization grade of bone. Tartrate-resistant acid phos-
phatase (TRAP) staining was applied to determine osteo-
clastic activity. To perform TRAP staining, the sections were
deparaffinized and preincubated in 0.2 M TRIS-magnesium
chloride (MgCl2) buffer (pH 9.0) for 2 h at 378C. After rinsing
with distilled water, the sections were incubated in a solution
consisting of hexazotized pararosaniline (4 mL), naphthol AS-
BI phosphate (25mg), N,N-dimethylformamide (2.5 mL),
veronal buffer (12.5mL), and MgCl2 (0.5 g) (pH 5.0) at 378C.
Positive staining developed within 30 min. The sections were
then counterstained for 1 min with hematoxylin, rinsed in
water, dehydrated, and mounted with di-N-butyl phthalate
in xylene (BDH Laboratory Supplies, Poole, England). Posi-
tive control sections were included.
FIG. 1. Size distribution of the high-molecular-weight
(HMW; black bar) and low-molecular-weight (LMW; grey
bar) poly(DL-lactic-co-glycolic acid) (PLGA) microparticles
prepared using a double-emulsion solvent-extraction tech-
nique (group size¼ 200).
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Statistical analysis
Statistical analysis was performed using GraphPad Instat
version 3.05 (GraphPad Software Inc., San Diego, CA), using
an unpaired t-test with Welch correction and a one-way
analysis of variance (ANOVA). Differences were considered
significant at p-values less than 0.05.
Results
Characterization of PLGA microparticles
Figure 1 shows the size distribution of the HMW and LMW
PLGA microparticles prepared using a double-emulsion sol-
vent-extraction technique. The average size of the micropar-
ticles, as determined with image analysis, was 20 18mm for
the HMW PLGA and 21 14mm for the LMW PLGA. SEM
images revealed spherical particles with a smooth surface for
the HMW (Fig. 2A) and the LMW particles (Fig. 2B).
Characterization of CaP cement composites
In Table 1, the total porosity and macroporosity of the
different implant formulation are shown. The 100HMW im-
plants were significantly less porous than the other implants
(ANOVA). No significant differences in porosity were seen
between the other formulations. After the composites were
removed from the molds, SEM images showed intact HMW
PLGA microparticles incorporated into the CaP cement (Fig.
3A). The major part of the LMW PLGA microparticles, on the
other hand, was more or less fused with the cement (Fig. 3B).
Descriptive light microscopy
Figure 4 shows an overview of the histological sections of
the different formulations after 12 weeks of implantation.
The integrity of the implants was maintained for all groups.
Minimal edge degradation with rounded implant edges was
seen in the 100HMW and 25LMW groups (Fig. 4A, B), where
FIG. 2. Scanning electron
microscopy (SEM) images of
(A) HMW and (B) LMW
PLGA microparticles.
Table 1. Percentage of Total Porosity
and Macroporosity in the Different
Implant Formulations
Total porosity (%) Macroporosity (%)
Mean Standard Deviation
100HMW 65.8 0.6* 42.1 0.9*
25LMW 69.1 1.5 47.7 2.4
50LMW 70.1 0.5 49.5 0.9
75LMW 70.7 0.5 50.4 0.8
100LMW 69.6 1.2 48.6 2.1
The 100% high-molecular-weight (HWW) poly(DL-lactic-co-
glycolic acid) implants (100HMW) were significantly (*) less porous
than the other groups ( p< 0.001, analysis of variance).
LMW, low molecular weight.
FIG. 3. SEM images of (A) 100% HMW and (B) 100% LMW
PLGA–calcium phosphate (CaP) cement composites before
implantation.
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in the groups with 50% or more LMW PLGA microparticles
(Fig. 4C-E), implant degradation had clearly occurred, with
the highest degree in the 100LMW group. All formulations
showed ingrowth of bone, fibrous tissue, or bone marrow–
like tissue in the superficially located PLGA pores. However,
in the center of the implants, cells were found only in the
75LMW and 100LMW groups (Fig. 5A) and not in the
100HMW, 25LMW, or 50LMW specimens (Fig. 5B). None of
the specimens revealed signs of inflammation, as character-
ized by the absence of inflammatory cells.
Bone formation was seen at the defect edges and dura side
of all specimens, with the greatest amount of bone in the
groups with a higher percentage of LMW PLGA micropar-
ticles. Mature bone was deposited directly onto the cement
surface, without an intervening fibrous tissue layer, and
enclosed bone marrow–like tissue in the specimens with 50%
or more LMW PLGA microparticles (Fig. 6). Bone bridging,
as characterized by a bone layer covering the whole defect at
the dura side, was seen in none of the 100HMW, one
25LMW, two 50LMW, five 75LMW, and five 100LMW im-
plants out of six implants per group (Fig. 4A-E).
TRAP staining revealed osteoclastic activity in all samples.
The descriptive evaluation indicated that the TRAP staining
was positive primarily in the implants with a larger amount
of LMW PLGA microparticles, indicating extensive active
bone remodeling in these specimens (Fig. 7).
Fluorescence microscopy confirmed that bone formation
started at the dura side, because green bands were detected
here (calcein administered 6 weeks postoperatively) and then
continued toward the periosteum (red bands of alizarin com-
plexon administered 11 weeks after surgery) (Fig. 8). Yellow
tetracycline bands (1 week postoperatively) were found
mainly at the defect edges.
Histomorphometry
The histomorphometrical results are depicted in Table 2.
All implant types showed significant degradation after 12
FIG. 4. Histological sections of the different formulations
after 12 weeks of implantation. (A) 100% HMW; (B) 25%
LMW, (C) 50% LMW, (D) 75% LMW and (E) 100% LMW
PLGA–CaP cement composites. Methylene blue and basic
fuchsin staining. Color images available online at www
.liebertonline.com=ten.
FIG. 5. Histological sections showing the center of a (A)
100% LMW and (B) 25% LMW implant. Goldner’s Masson
trichrome staining. Cellular ingrowth was not seen in the
center of the 25% LMW implant. Color images available
online at www.liebertonline.com=ten.
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weeks of implantation from the initial (t¼ 0) amount of ce-
ment (unpaired t-test with Welch correction, p< 0.01).
Comparing the relative decreases (D T0=12) in amount of
implant after 12 weeks of implantation of the different for-
mulations, it appeared that 100HWW and 25LMW were
similar and were significantly less degraded than the similar
groups of 50LMW and 75LMW (unpaired t-test with Welch
correction, p< 0.01). In addition, the relative decrease of the
100LMW implants after 12 weeks (40 6%) was significantly
greater than for all other formulations (unpaired t-test with
Welch correction, p< 0.003).
The percentage of new bone formation was comparable
between the 100HMW and 25LMW groups. Also, bone for-
mation in the 50LMW group was not significantly different
from the 100HMW and 25LMW formulations (unpaired
t-test with Welch correction, p¼ 0.08 and p¼ 0.06, respec-
tively). Bone formation in the 75LMW implants was signifi-
cantly greater than in these groups ( p< 0.04). However, the
100LMW showed the significantly greatest amount of newly
formed bone (26 6%) (unpaired t-test with Welch correc-
tion, p< 0.02).
Discussion
CaP cements are promising materials that can be used in
diverse targeted bone-related treatments, but their degrada-
tive behavior is a property that has to be optimized.7 In the
present study, PLGA microparticles were incorporated into
CaP cement with diverse proportions of LMW and HMW
PLGA to investigate the influence of molecular weight on
bioactive behavior. A higher percentage of LMW PLGA
microparticles in the composites was associated with a better
bone biological response. In the current study, no control
materials without addition of PLGA were included. Ex-
tensive previous animal testing had proved that the degra-
dation of nonporous CaP cement is limited.20–22
Composites of PLGA and CaP cement have been shown to
be biocompatible and to form macroporous scaffolds after
polymer degradation in previous in vitro studies or in non-
critical-sized animal models.10,12,23–25 Also, in the present
study, using a critical-sized defect model, all formulations of
PLGA and CaP cement showed biocompatibility and some
bone ingrowth into the PLGA pores. Nevertheless, differ-
ences were seen between the formulations, with a higher
amount of LMW PLGA resulting in better implant degra-
dation and bone ingrowth. PLGA is a synthetic polymer that
degrades via a random hydrolytic mechanism that is de-
pendent on several factors, including molecular weight.16,26
Low molecular weight PLGA degrades faster than high
molecular weight PLGA.16,27 Habraken et al.11 determined
the Mw loss of PLGA microparticles with a Mw similar to
that of our HMW group (48.0 1.6 kDa) inside CaP cement
samples when incubated in phosphate buffered saline at
378C. They found that a linear decrease with approximately
20% PLGA remained after 6 weeks and complete degrada-
tion after 12 weeks of incubation. In contrast, LMW PLGA
microparticles (4.54 0.03 kDa) showed a Mw loss of ap-
proximately 50% after 4 weeks and complete degradation
after 6 weeks (unpublished data). As in the present study, no
FIG. 6. Mature bone (B) with bone marrow–like tissue (Bm)
was deposited directly onto the cement surface (C) of a 100%
LMW implant. Methylene blue and basic fuchsin staining.
Color images available online at www.liebertonline.com=ten.
FIG. 7. Tartrate-resistant acid phosphatase–positive cells in
(A) 100% LMW and (B) 100% HMW implants. Color images
available online at www.liebertonline.com=ten.
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significant difference was seen in microparticle size between
HMW and LMW PLGA or in porosity between the 25LMW,
50LMW, 75LMW, and 100LMW samples; this different rate
of PLGA degradation most probably explains the differences
noticed in implant degradation and bone ingrowth between
the groups. Evidently, a high percentage of fast-degrading
LMW PLGA in the CaP cement composites facilitated the
formation of a macroporous structure and thereby the deg-
radation of the implant, followed by bone ingrowth. Con-
sidering the observed degradation of the 75LMW and
100LMW samples and the lack of PLGA degradation and
tissue ingrowth into the other materials, there seems to be no
direct correlation between the originally ‘‘designed’’ material
porosity (by the inclusion of PLGA microparticles) and final
bone ingrowth. Apparently, the driving factor for bone in-
growth is PLGA degradation. Degradation appeared to be
associated with osteoclast activity, because TRAP-positive
cells were detected in all formulations but especially in the
high LMW (75 and 100 LMW) groups. Bone formation started
at the defect edges and dura side, as displayed with fluo-
rescent labeling, and then continued toward the periosteal
side, which is consistent with preceding investigations28,29
and is probably explained by the presence of preosteoblastic
cells in the dura mater.28 The rate of degradation and bone
ingrowth were similar, because the integrity of the scaffolds
was maintained. For future studies, it would be interesting
to perform mechanical tests to determine the shear strength
of the implants.
SEM images generated of the composites before implan-
tation revealed an important difference in structure between
the formulations. Although the HMW microparticles showed
the same morphology in the cement as before the mixing
procedure, the LMW microparticles lost their spherical
shape, and the majority were fused with the CaP cement.
This observation can explain why the percentage of implant
seems to be LMW concentration dependant at T0 (Table 2).
Furthermore, this finding might indicate a different inter-
connectivity between the groups (i.e., the merging of the
LMW PLGA microparticles within the CaP cement improved
the interconnection between the particles). The possession of
a network of linked pores is an important criterion for bio-
materials because it enables cellular and vascular penetration,
and bone ingrowth inside scaffolds is thereby favored.30
Interconnectivity between spheres in a solid matrix is sup-
posed to be present when the volume fraction exceeds 0.4.31
The 100HMW group just surpassed this limit, with 42%
macroporosity; all the other formulations possessed a mac-
roporosity or approximately 50% and should have had an
interconnective system confirm this hypothesis. Nevertheless,
only the 75LMW and 100LMW formulations showed cellular
ingrowth throughout the sample, indicating that the parti-
cles were interconnected. The 25LMW and 50 LMW groups
might possess an interconnective system, but because of the
poor degradation of the HMW PLGA microspheres within 12
weeks of implantation, this could not be detected in the
present study.
As stated above, differences between the 100HMW and
100LMW groups were seen in cellular entry in the middle of
the implant. Tissue ingrowth throughout the implants as
seen in the study of Ruhe´ et al.12 where non-critical sized
defects were created, was only noticed in the 75LMW and
100LMW samples. Apparently, the microparticles in the
groups containing less LMW PLGA were entrapped in the
center of the implant and thereby withdrawn from necessary
FIG. 8. Fluorescence microscopic image of a 100% LMW
implant (C). Ca, calcein green administered 6 weeks after
surgery; A, alizarin complexon red administered 11 weeks
after surgery; P, periosteal side of the implant; D, dural side
of the implant; B, bone. Color images available online at
www.liebertonline.com=ten.






Difference in % of
Implant Between the
Two Time Points
% BoneMean Standard Deviation
100 HMW 84 3 74 3 10 3 8 2
25 LMW 81 2 72 4 8 4 9 1
50 LMW 86 4 65 3 21 3 11 2
75 LMW 86 3 65 8 21 8 17 5
100 LMW 90 2 50 6 40 6 26 6
T¼ 0: before implantation; t¼ 12 weeks: after 12 weeks implantation; D T0=12: difference in % of implant between the two time points.
HMW, high molecular weight; LMW, low molecular weight.
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fluids for degradation. This entrapment might also cause
problems at a later time point, as described by Ignatius
et al.,32 who implanted composites of PLA (Mw 91 kDa) and
alpha-tocopherol in tibial bone defects of sheep for 6, 12, and
24 months. After 6 and 12 months of implantation, the im-
plants were filled with newly formed bone, and only a mild
inflammatory response was observed, but after 24 months,
a strong inflammatory reaction was seen, and the newly
formed bone was partly osteolytic. It was suggested that
newly formed bone had encapsulated the acid degradation
products of PLA, which degraded at this later time point and
caused the adverse reaction. A better coordination of the
degradation times of the polymer and ceramic component
was recommended. The coordination in degradation seemed
to be effective in our predominantly LMW PLGA compos-
ites, with PLGA degradation in these scaffolds occurring at
an early moment when no capsule was present and clearing
of the acid products was not prevented, resulting in healing
of the critical-sized bone defects.
For all formulations, the dimension of the microparticles
and thereby the pore size of the scaffolds was smaller than in
previous studies of osteoconductive biomaterials. In general,
it is said that a pore size of at least 50 to 100 mm is necessary
to allow bone formation,33,34 although the narrow pore size
of 21 14 mm appeared to be large enough in our LMW
PLGA group to obtain cellular entry and bone ingrowth
throughout the implants. Lu et al.30 stated that, in addition to
pore size, the density of interconnections in porous bio-
ceramics plays an important role for bone formation, and this
seems also to be true of our LMW implants.
The finding that composites of CaP cement and LMW
PLGA microparticles are able to bridge critical-sized cranial
defects without the inclusion of growth factors is most im-
portant. The amount of bone ingrowth in the LMW samples
(26 6%) was considerably higher than in HMW implants,
including recombinant human bone morphogenetic protein 2
(16 2%), as we found recently using exactly the same ani-
mal model and implantation time.15 So far, we know of no
previous studies that were able to show that critical-sized
defects could be healed with a material containing no growth
factors. This is important because growth factors are costly
and there are significant problems with the bioavailability of
these compounds when included in CaP materials.15 Whe-
ther the combination of LMW PLGA with growth factors has
even superior bone biological behavior deserves further in-
vestigation.
Conclusion
In conclusion, the molecular weight of PLGA in CaP ce-
ment composites influences implant degradation and new
bone formation. A higher percentage of fast-degrading LMW
PLGA microparticles increases the biological activity of the
composites more than HMW PLGA microparticles. The lar-
ger interconnectivity in the LMW samples probably explains
this difference. Composites with 100% LMW PLGA micro-
particles are capable of bridging critical-sized cranial defects
without the inclusion of growth factors.
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